- Home
- HQI vs CLLS Comparison
HQI vs CLLS Comparison
Compare HQI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- CLLS
- Stock Information
- Founded
- HQI 2002
- CLLS 1999
- Country
- HQI United States
- CLLS France
- Employees
- HQI N/A
- CLLS N/A
- Industry
- HQI Professional Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- CLLS Health Care
- Exchange
- HQI Nasdaq
- CLLS Nasdaq
- Market Cap
- HQI 143.3M
- CLLS 144.4M
- IPO Year
- HQI N/A
- CLLS 2007
- Fundamental
- Price
- HQI $9.82
- CLLS $1.49
- Analyst Decision
- HQI Strong Buy
- CLLS Buy
- Analyst Count
- HQI 2
- CLLS 3
- Target Price
- HQI $16.00
- CLLS $6.67
- AVG Volume (30 Days)
- HQI 16.9K
- CLLS 46.6K
- Earning Date
- HQI 05-08-2025
- CLLS 05-12-2025
- Dividend Yield
- HQI 2.40%
- CLLS N/A
- EPS Growth
- HQI N/A
- CLLS N/A
- EPS
- HQI 0.24
- CLLS N/A
- Revenue
- HQI $33,651,000.00
- CLLS $54,747,000.00
- Revenue This Year
- HQI N/A
- CLLS $48.52
- Revenue Next Year
- HQI $4.99
- CLLS $5.17
- P/E Ratio
- HQI $38.46
- CLLS N/A
- Revenue Growth
- HQI N/A
- CLLS 351.26
- 52 Week Low
- HQI $9.04
- CLLS $1.10
- 52 Week High
- HQI $15.75
- CLLS $2.78
- Technical
- Relative Strength Index (RSI)
- HQI 47.07
- CLLS 51.15
- Support Level
- HQI $9.13
- CLLS $1.46
- Resistance Level
- HQI $10.00
- CLLS $1.60
- Average True Range (ATR)
- HQI 0.44
- CLLS 0.08
- MACD
- HQI 0.12
- CLLS -0.01
- Stochastic Oscillator
- HQI 61.61
- CLLS 52.17
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.